2-methyl-hex-4c-en-3-one | 50396-99-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-hex-4c-en-3-one
• 英文别名: (Z)-2-methylhex-4-en-3-one
• CAS: 50396-99-1
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: QSACGCAUVMLJNS-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-甲基吡咯烷酮 、 2-methyl-hex-4c-en-3-one 、 lithium diisopropyl amide 生成 3-[(Z)-3-hydroxy-2-methylhex-4-en-3-yl]-1-methylpyrrolidin-2-one
  参考文献：
  名称：

  OARE, DAVID A.;HENDERSON, MARK A.;SANNER, MARK A.;HEATHCOCK, CLAYTON H., J. ORG. CHEM., 55,(1990) N, C. 132-157

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲基-2-丁酮 在 草酸 、 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 2-methyl-hex-4c-en-3-one
  参考文献：
  名称：

  Conformational effects of alkyl groups on the .pi. .far. .pi.* transitions of .alpha.-enones

  摘要：

  DOI：

  10.1021/ja00803a023

文献信息

• Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
  申请人：Hodous Brian L.

  公开号：US20140162983A1

  公开（公告）日：2014-06-12

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了新型嘧啶和吡啶化合物，其符合公式（I），公式（II），公式（III），公式（IV）和公式（V），以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症，狼疮，过敏性疾病，Sjogren's病和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
  申请人：Merck Patent GmbH

  公开号：US20150259363A1

  公开（公告）日：2015-09-17

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了新的嘧啶和吡啶化合物，包括式(I)、式(II)、式(III)、式(IV)和式(V)，以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症、狼疮、过敏性疾病、干燥综合症和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• Bruton's Tyrosine Kinase Inhibitors
  申请人：PFIZER INC.

  公开号：US20150291554A1

  公开（公告）日：2015-10-15

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。披露了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。披露了使用BTK抑制剂的方法，单独或与其他治疗剂一起，用于治疗自身免疫性疾病或状况、异种免疫性疾病或状况、包括淋巴瘤的癌症和炎症性疾病或状况。
• Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
  申请人：Merck Patent GmbH

  公开号：US10016448B2

  公开（公告）日：2018-07-10

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了根据式(I)、式(II)、式(III)、式(IV)和式(V)制造和使用的新型嘧啶和吡啶化合物，用于治疗过度增殖性疾病，包括但不限于癌症、狼疮、过敏性疾病、Sjogren病和类风湿性关节炎。在优选的实施方案中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
  申请人：HyperBranch Medical Technology, Inc.

  公开号：US10688216B2

  公开（公告）日：2020-06-23

  One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visible light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneimine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.

  本发明的一个方面一般涉及密封伤口或组织平面或填充空隙的方法。在一个优选的实施方案中，伤口是眼科、胸膜或硬脑膜伤口。在某些情况下，用于密封伤口或组织平面的组合物包括聚亚烷基亚胺。在一个优选的实施方案中，聚烯亚胺是聚乙烯亚胺。用交联试剂处理聚乙烯亚胺可使聚乙烯亚胺聚合物聚合形成密封。在某些情况下，交联试剂是具有活性末端基团的聚乙二醇。在某些情况下，活性末端基团是活化酯，如 N-羟基琥珀酰亚胺酯。在某些情况下，活性末端基团是异氰酸酯。在某些情况下，聚乙烯亚胺的聚合物外围附有赖氨酸、半胱氨酸、异半胱氨酸或其他亲核基团。在某些情况下，聚乙烯亚胺与第二种聚合物混合，例如含有亲核基团的聚乙二醇。在某些情况下，用于密封伤口或组织平面的组合物是由含亲电基团的聚亚烷基亚胺与含亲核基团的交联试剂反应形成的。在某些情况下，聚亚烷基亚胺上的亲电基团是活化酯，如 N-羟基琥珀酰亚胺酯。在某些情况下，用于密封伤口或组织平面的组合物是通过使带有可光聚合基团的聚亚烃亚胺与紫外线或可见光反应而形成的。用于密封伤口的组合物含有 PEI 或 PEI 的衍生物，可与组织紧密粘合。本发明的其他方面涉及填补患者或粘附组织空隙的方法。在某些情况下，这些方法使用聚烯亚胺。在一个优选的实施方案中，聚烯亚胺是聚乙烯亚胺。本发明的另一方面涉及一种聚合组合物，该组合物通过将聚亚烷酰亚胺与活化的聚亚烷二醇接触而形成。在某些情况下，该组合物附着在哺乳动物组织上。